Outcome of Patients with Acute Myocardial Infarction Who Are Ineligible for Thrombolytic Therapy
Overview
Authors
Affiliations
Objective: To determine what proportion of patients with acute myocardial infarction are not eligible for thrombolytic therapy and to assess their natural history.
Design: Retrospective chart review.
Setting: A large community-based hospital.
Patients: All patients with acute myocardial infarction hospitalized during a 27-month period.
Measurements: Of 1471 patients with acute myocardial infarction, 230 (16%) received thrombolytic therapy according to the protocol and an additional 97 (7%) received nonprotocol thrombolytic therapy, primary coronary balloon angioplasty, or both because of contraindications. The other 1144 patients (78%) did not receive reperfusion therapy.
Main Results: The patients who did not receive thrombolytic therapy were older, more likely to be women, and more likely to have a history of hypertension, previous myocardial infarction, or chronic angina (all comparisons, P less than 0.002). An average of 1.9 reasons for exclusion were identified per patient among the ineligible patients. Mortality was fivefold higher among ineligible patients (19%; Cl, 16% to 21%) than among protocol-treated patients (4%; Cl, 1% to 6%) (P less than 0.001). In-hospital mortality rates for excluded patients were 28% (Cl, 23% to 32%) in elderly patients (age, greater than 76 years; n = 396); 29% (Cl, 23% to 35%) in patients with stroke or bleeding risk (n = 209); 17% (Cl, 14% to 20%) in patients with delayed presentation (greater than 4 hours after the onset of chest pain; [n = 599]); 14% (Cl, 11% to 16%) in patients with an ineligible electrocardiogram (ECG) (n = 673); and 26% (Cl, 21% to 32%) in patients with a miscellaneous reason for exclusion (n = 243). Independent predictors of increased mortality were: age greater than 76 years, stroke or other bleeding risk, ineligible ECG, or the presence of two or more exclusion criteria.
Conclusions: Thrombolytic therapy is currently used in the United States for only a minority of patients with acute myocardial infarction: those who have low-risk prognostic characteristics.
Dynamic TIMI risk score for STEMI.
Amin S, Morrow D, Braunwald E, Sloan S, Contant C, Murphy S J Am Heart Assoc. 2013; 2(1):e003269.
PMID: 23525425 PMC: 3603245. DOI: 10.1161/JAHA.112.003269.
Defining optimal therapy for the thrombolysis-ineligible patient.
Cohen M Clin Cardiol. 2002; 25(11 Suppl 1):I23-6.
PMID: 12428816 PMC: 6654174. DOI: 10.1002/clc.4960251306.
Sugiura T, Yamasaki F, Hatada K, Nakamura S, Iwasaka T Clin Cardiol. 2002; 24(12):770-4.
PMID: 11768740 PMC: 6655111. DOI: 10.1002/clc.4960241204.
Steg And Patrick Seknadji PG J Thromb Thrombolysis. 1997; 4(3/4):331-336.
PMID: 10639637 DOI: 10.1023/a:1008837014116.
The role of coronary angioplasty and stenting in acute myocardial infarction.
Brodison A, More R, Chauhan A Postgrad Med J. 2000; 75(888):591-8.
PMID: 10621899 PMC: 1741380. DOI: 10.1136/pgmj.75.888.591.